Brief communication: Morphoproteomic confirmation of constitutively activated mTOR, ERK, and NF-kappaB pathways in high risk neuroblastoma, with cell cycle and protein analyte correlates

Annals of Clinical and Laboratory Science

Volumn 37, Issue 2, 2007, Pages 141-147

  Brown, Robert E ^a   Tan, Dongfeng ^b   Taylor, Jeffrey S ^c   Miller, Michal ^c   Prichard, Jeffrey W ^c   Kott, Marylee M ^a  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c GEISINGER MEDICAL CENTER   (United States)

Author keywords

Cell cycle; ERK; Morphoproteomics; mTOR; Neuroblastoma; NF kappaB

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEIN BCL 2; S PHASE KINASE ASSOCIATED PROTEIN 2; MITOGEN ACTIVATED PROTEIN KINASE; NFKB1 PROTEIN, HUMAN; PROTEIN KINASE; S PHASE KINASE ASSOCIATED PROTEIN; S6 KINASE; TUMOR ANTIGEN; TUMOR MARKER; UNCLASSIFIED DRUG;

ARTICLE; CANCER RISK; CELL CYCLE; HUMAN; HUMAN CELL; NEUROBLASTOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEOMICS; BRAIN TUMOR; CANCER STAGING; CELL NUCLEUS; METABOLISM; PATHOLOGY; PHYSIOLOGY;

ANTIGENS, NEOPLASM; BRAIN NEOPLASMS; CELL CYCLE; CELL NUCLEUS; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; HUMANS; NEOPLASM STAGING; NEUROBLASTOMA; NF-KAPPA B P50 SUBUNIT; PROTEIN KINASES; PROTEOMICS; RIBOSOMAL PROTEIN S6 KINASES, 70-KDA; S-PHASE KINASE-ASSOCIATED PROTEINS; TUMOR MARKERS, BIOLOGICAL;

EID: 34248226458     PISSN: 00917370     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. Matthay KK, Villablanca JG, Seeger RC, Stram DO, Harris RE, Ramsay NK, Swift P, Shimada H, Black CT, Brodeur GM, Gerbing RB, Reynolds CP. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid, Children's Cancer Group. NEJM 1999;341:1165-1173.
2. Misawa A, Hosoi H, Tsuchiya K, Sugimoto T. Rapamycin inhibits proliferation of human neuroblastoma cells without suppression of MycN. Int J Cancer 2003;104:233-237.
3. Eppstein AC, Sandoval JA, Klein PJ, Woodruff HA, Grosfeld JL, Hickey RJ, Malkas LH, Schmidt CM. Differential sensitivity of chemoresistant neuroblastoma subtypes to MAPK-targeted treatment correlates with ERK, p53 expression, and signaling response to U0126. J Pediatr Surg 2006;41:252-259.
4. Brignole C, Marimpietri D, Pastorino F, Nico B, Di Paolo D, Cioni M, Piccardi F, Cilli M, Pezzolo A, Corrias MV, Pistoia V, Ribatti D, Pagnan G, Ponzoni M. Effect of bortezomib on human neuroblastoma cell growth, apoptosis and angiogenesis. J Natl Cancer Inst 2006;98:1142-1157.
5. Michealis M, Fichtner I, Behrens D, Haider W, Rothweiler F, Mack A, Cinatl J, Doerr HW, Cinatl J Jr. Anti-cancer effects of bortezomib against chemoresistant neuroblastoma cell lines in vitro and in vivo. Int J Oncol 2006;28:439-446.
6. Chiarle R, Fan Y, Piva R, Boggino H, Skolnik J, Novero D, Palestro G, De Wolf-Peeters C, Chilosi M, Pagano M, Inghirami G. S-phase kinase-associated protein 2 expression in non-Hodgkin's lymphoma inversely correlates with p27 expression and defines cells in S phase. Am J Pathol 2002;160:1457-1466.
7. Brown RE, Lun M, Prichard JW, Blasick TM, Zhang PL. Morphoproteomic and pharmacoproteomic correlates in hormone-receptor-negative breast carcinoma cell lines. Ann Clin Lab Sci 2004;34:251-262.
8. Brown RE. Morphoproteomics: exposing protein circuitries in tumors to identify potential therapeutic targets in cancer patients. Expert Rev Proteomics 2005;2:337-348.
9. Cao X, Kambe F, Moeller LC, Refetoff S, Seo H. Thyroid hormone induces rapid activation of Akt/ protein kinase B-mammalian target of rapamycin-p70S6K cascade through phosphatidylinositol 3-kinase in human fibroblasts. Mol Endocrinol 2005;19:102-112.
10. Nave BT, Ouwens M, Withers DJ, Alessi DR, Shepherd PR. Mammalian target of rapamycin is a direct target for protein kinase B: identification of a convergence point for opposing effects of insulin and amino-acid deficiency on protein translation. Biochem J 1999; 344:427-431.
11. Pullen N, Dennis PB, Andjelkovic M, Dufner A, Kozma SC, Hemmings BA, Thomas G. Phosphorylation and activation of p70s6k by PDK1. Science 1998;279:707-710.
12. Dennis PB, Pullen N, Kozma SC, Thomas G. The principal rapamycin-sensitive p70 (s6k) phosphorylation sites, T-229 and T-389, are differentially regulated by rapamycin-insensitive kinase kinases. Mol Cell Biol 1996;16:6242-6251.
13. Valentinis B, Navarro M, Zanocco-Marani T, Edmonds P, McCormick J, Morrione A, Sacchi A, Romano G, Reiss K, Baserga R. Insulin receptor substrate-1, p70S6K, and cell size in transformation and differentiation of hemopoietic cells. J Biol Chem 2000;275:25451-25459.
14. Xu G, Zhang W, Bertram P, Zheng XF, McLeod H. Pharmacogenomic profiling of the PI3K/PTEN-AKT-mTOR pathway in common human tumors. Int J Oncol 2004;24:893-900.
15. Ali SM, Sabatini DM. Structure of S6 kinase 1 determines whether raptor-mTOR or rictor-mTOR phosphorylates its hydrophobic motif site. J Biol Chem 2005;280:19445-19448.
16. Kim SJ, Kahn CR. Insulin stimulates p70 S6 kinase in the nucleus of cells. Biochem Biophys Res Commun 1997;234:681-685.
17. Chow S, Patel H, Hedley DW. Measurement of MAP kinase activation by flow cytometry using phosphospecific antibodies to MEK and ERK: potential for pharmacodynamic monitoring of signal transduction inhibitors. Cytometry 2001;46:72-78.
18. Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, Rong H, Chen C, Zhang X, Vincent P, McHugh M, Cao Y, Shujath J, Gawlak S, Eveleigh D, Rowley B, Liu L, Adnane L, Lynch M, Auclair D, Taylor I, Gedrich R, Voznesensky A, Riedl B, Post LE, Bollag G, Trail PA. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis.Cancer Res 2004; 64:7099-7109.
19. Adnane L, Trail PA, Taylor I, Wilhelm SM. Sorafenib (BAY 43-9006, Nexavar), a dual-action inhibitor that targets RAF/MEK/ERK pathway in tumor cells and tyrosine kinases VEGFR/PDGFR in tumor vasculature. Meth Enzymol 2005;407:597-612.
20. Murphy DA, Makonnen S, Lassoued W, Feldman MD, Carter C, Lee WM. Inhibition of tumor endothelial ERK activation, angiogenesis, and tumor growth by Sorafenib (BAY43-9006). Am J Pathol 2006;169:1875-1885.
21. Korner M, Tarantino N, Pleskoff O, Lee LM, Debre P. Activation of nuclear factor kappa B in human neuroblastoma cell lines. J Neurochem 1994:62:1716-1726.
22. Feng Z, Porter AG. NF-kappaB/Rel proteins are required for neuronal differentiation of SH-SY5Y neuroblastoma cells. J Biol Chem 1999: 274 (43): 30341-30344.
23. Dominic C, Negroni A, Romeo A, McDowell H, Padula A, Pucci S, Cappelli C, Castello MA, Raschella G. Flow cytometric and molecular analysis of proliferative activity and DNA content in neuroblastoma: presence of stationary cells in S phase. Anticancer Res 1992;12:59-63.
24. Huddart SN, Muir KR, Parkes SE, Mann JR, Stevens MC, Raafat F, Smith K. Retrospective study of prognostic value of DNA ploidy and proliferative activity in neuroblastoma. J Clin Pathol 1993;46:1101-1104.
25. Brown RE, Zhang PL, Lun M, Zhu S, Pellitteri PK, Law A, Riefkohl W, Wood GC, Kennedy TL. Morphoproteomic and pharmacoproteomic rationale for mTOR effectors as therapeutic targets in head and neck squamous cell carcinoma. Ann Clin Lab Sci 2006;36:273-282.
26. Bancroft CC, Chen Z, Yeh J, Sunwoo JB, Yeh NT, Jackson S, Jackson C, Van Waes C. Effects of pharmacologic antagonists of epidermal growth factor receptor, PI3K and MEK signal kinases on NF-kappaB and AP-1 activation and IL-8 and VEGF expression in human head and neck squamous cell carcinoma lines. Int J Cancer 2002;99:538-548.
27. Ichikawa H, Takada Y, Murakami A, Aggarwal BB. Identification of a novel blocker of I kappa B alpha kinase that enhances cellular apoptosis and inhibits cellular invasion through suppression of NF-kappaB-regulated gene products. J Immunol 2005;174:7383-7392.
28. Lin F, Zhang PL, Yang XJ, Prichard JW, Lun M, Brown RE. Morphoproteomic and molecular concomitants of an overexpressed and activated mTOR pathway in renal cell carcinomas. Ann Clin Lab Sci 2006;36:283-293.
29. Ogawa M, Hori H, Ohta T, Onozato K, Miyahara M, Komada Y. Sensitivity to gemcitabine and its metabolizing enzymes in neuroblastoma. Clin Cancer Res 2005; 11:3485-3493.
30. Chun PY, Feng FY, Scheurer AM, Davis MA, Lawrence TS, Nyati MK Synergistic effects of gemcitabine and gefitinib in the treatment of head and neck carcinoma. Cancer Res 2006;66:981-988.
31. Iehara T, Hosoi H, Akazawa K, Matsumoto Y, Yamamoto K, Suita S, Tajiri T, Kusafuka T, Hiyama E, Kaneko M, Sasaki F, Sugimoto T, Sawada T. MYCN gene amplification is a powerful prognostic factor even in infantile neuroblastoma detected by mass screening. Br J Cancer 2006;94:1510-1515.
32. Chambery D, Mohseni-Zadeh S, de Galle B, Babajko S. N-myc regulation of type I insulin-like growth factor receptor in a human neuroblastoma cell line. Cancer Res 1999;59:2898-2902.
33. Jasty R, van Golen C, Lin HJ, Solomon G, Heidelberger K, Polverini P, Opipari A, Feldman E, Castle VP. Bcl-2 and M-Myc coexpression increases IGF-IR and features of malignant growth in neuroblastoma cell lines. Neoplasia 2001;3:304-313.
34. Misawa A, Hosoi H, Arimoto A, Shikata T, Akioka S, Matsumura T, Houghton PJ, Sawada T. N-Myc induction stimulated by insulin-like growth factor I through mitogen-activated protein kinase signaling pathway in human neuroblastoma cells. Cancer Res 2000;60:64-69.
35. Wittrock J, Schweizer P, Girgert R. Induction of N-myc in neuroblastoma by autocrine IGF-II depends on farnesylated Ras. Application of farnesyltransferase inhibitors. Anticancer Res 2002;22:4205-4209.
36. Ren Y, Chan HM, Li Z, Lin C, Nicholls J, Chen CF, Lee PY, Lui V, Bacher M, Tam PK. Upregulation of macrophage migration inhibitory factor contributes to induced N-Myc expression by the activation of ERK signaling pathway and increased expression of interleukin-8 and VEGF in neuroblastoma. Oncogene 2004;23:4146-4154.
37. Spitz R, Hero B, Simon T, Berthold F. Loss in chromosome 11q identifies tumors with increased risk for metastatic relapses in localized and 4S neuroblastoma. Clin Cancer Res 2006;12:3368-3373.
38. Smith M, Smalley S, Cantor R, Pandolfo M, Gomez MI, Baumann R, Flodman P, Yoshiyama K, Nakamura Y, Julier C, Dumars K, Haines J, Trofatter J, Spence MA, Weeks D, Conneally M. Mapping of a gene determining tuberous sclerosis to human chromosome 11q14-11q23. Genomics 1990;6:105-114.
39. Janssen LA, Sandkuyl LA, Merkens EC, Maat-Kievit JA, Sampson JR, Fleury P, Hennekam RC, Grosveld GC, Lindhout D, Halley DJ. Genetic heterogeneity in tuberous sclerosis. Genomics 1990;8:237-242.
40. Tee AR, Manning BD, Roux PP, Cantley LC, Blenis J. Tuberous sclerosis complex gene products, tuberin and hamartin, control mTOR signaling by acting as a GTPase-activating protein complex toward Rheb. Curr Biol 2003;13:1259-1268.
41. Ryan DP, Appleman LJ, Lynch T, Supko JG, Fidias P, Clark JW, Fishman M, Zhu AX, Enzinger PC, Kashala O, Cusack J Jr, Eder JP. Phase I clinical trial of bortezomib in combination with gemcitabine in patients with advanced solid tumors. Cancer 2006;107:2482-2489.
42. Kitamura Y, Kosaka T, Shimohama S, Nomura Y, Taniguchi T. Possible involvement of rapamycin-sensitive pathway in Bcl-2 expression in human neuroblastoma SH-SY5Y cells. Jpn J Pharmacol 1997; 75:195-198.
43. Calastretti A, Rancati F, Ceriani MC, Asnaghi L, Canti G, Nicolin A. Rapamycin increases the cellular concentration of the BCL-2 protein and exerts an anti-apoptotic effect. Eur J Cancer 2001;37:2121-2128.
44. Chang GC, Hsu SL, Tsai JR, Wu WJ, Chen CY, Sheu GT. Extracellular signal-regulated kinase activation and Bcl-2 downregulation mediate apoptosis after gemcitabine treatment partly via a p53-independent pathway. Eur J Pharmacol 2004;502:169-183.